CRL Stock Overview
Charles River Laboratories International, Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Charles River Laboratories International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$187.90 |
| 52 Week High | US$275.00 |
| 52 Week Low | US$176.48 |
| Beta | 1.38 |
| 11 Month Change | -3.66% |
| 3 Month Change | -6.67% |
| 1 Year Change | -3.62% |
| 33 Year Change | -50.23% |
| 5 Year Change | 27.93% |
| Change since IPO | 754.09% |
Recent News & Updates
Recent updates
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19Shareholder Returns
| CRL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -9.0% | -7.2% | -1.2% |
| 1Y | -3.6% | 1.2% | 30.4% |
Return vs Industry: CRL underperformed the US Life Sciences industry which returned 1.2% over the past year.
Return vs Market: CRL underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International, Inc. Fundamentals Summary
| CRL fundamental statistics | |
|---|---|
| Market cap | US$9.52b |
| Earnings (TTM) | US$413.08m |
| Revenue (TTM) | US$4.06b |
23.3x
P/E Ratio2.4x
P/S RatioIs CRL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRL income statement (TTM) | |
|---|---|
| Revenue | US$4.06b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$1.46b |
| Other Expenses | US$1.05b |
| Earnings | US$413.08m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.08 |
| Gross Margin | 35.93% |
| Net Profit Margin | 10.17% |
| Debt/Equity Ratio | 60.1% |
How did CRL perform over the long term?
See historical performance and comparison